17 November 2025

Incanthera plc

("Incanthera" the "Company")

Aquis Showcase Investor Presentation

Incanthera plc (AQSE:INC), the company focused on innovative technologies in dermatology and oncology is pleased to announce that it will be presenting and exhibiting at the fourth Aquis Showcase conference on Wednesday, 19 November 2025.

The event will be held at the Royal College of Surgeons, 38-43 Lincoln's Inn Fields, London, WC2A 3PE.  Incanthera's Chairman, Tim McCarthy and CEO, Dr. Simon Ward, will be introducing the company to delegates and taking questions.

A copy of the presentation that will be made will be available on the Company's website at: https://www.incanthera.com/investors/results-reports-and-presentations/

For further information and tickets for the Aquis Showcase conference, please visit the event website at:

https://www.eventbrite.co.uk/e/aquis-showcase-tickets-1733700999359

For further information please contact:

Notes to Editors

About Incanthera plc

Incanthera is a UK-based, dermatology and oncology therapeutics company focusing on discovery and development of targeted solutions. The Company has developed sophisticated formulation and targeting technology platforms to address previously unavailable options across dermatology and oncology, delivering treatments specifically to a required site, enabling effective ingredients with precision targeting for optimal efficacy.

Identifying and developing innovative solutions to current clinical, commercially relevant unmet needs, Incanthera combines new technology from industry and leading academics, as well as its in-house development team, with its unique targeting delivery platform.

The Company's current focus is Skin + CELL, Incanthera's unique luxury skincare brand in a range of dermatological applications to meet currently unmet needs in the skincare market.

For more information on the Company please visit: www.incanthera.com

@incantheraplc

About Skin + CELL 

Skin + CELL is Incanthera's luxury skincare brand utilising, launched in August 2025. Our ground-breaking formulation and delivery expertise brings scientifically proven formulations to cosmetics. Skin + CELL's complementary range of products are based on advanced, clinically designed, formulation concentrates which combine leading edge delivery enhancement technology with selected prestige cosmetic ingredients to give an effective product which gives a silky emollience in use and leaves the skin visibly radiant, energised and protected.

Incanthera's new bioactive skincare technology has been developed by our in-house experts who have previously formulated topical products for some of the world's leading skincare and pharmaceutical companies. The formulations fortify otherwise depleted physiological pathways to improve the skin's performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.

Skin + CELL's luxury skincare current range extends across face, body, hand, face serum and eye cream, and will also include bioactive SPF concentrations and further derivatives of vitamins in the future.

www.skinandcell.com

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.